MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.86
-0.35 (-5.64%)
Feb 4, 2026, 2:34 PM EST - Market open
MannKind Employees
As of December 31, 2024, MannKind had 407 total employees, including 403 full-time and 4 part-time employees. The number of employees decreased by 7 or -1.69% compared to the previous year.
Employees
407
Change (1Y)
-7
Growth (1Y)
-1.69%
Revenue / Employee
$770,975
Profits / Employee
$71,826
Market Cap
1.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 407 | -7 | -1.69% | 403 | 4 |
| Dec 31, 2023 | 414 | 19 | 4.81% | 411 | 3 |
| Dec 31, 2022 | 395 | 46 | 13.18% | 391 | 4 |
| Dec 31, 2021 | 349 | 108 | 44.81% | 348 | 1 |
| Dec 31, 2020 | 241 | 8 | 3.43% | 240 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ardelyx | 395 |
| Vericel | 357 |
| Ocular Therapeutix | 274 |
| Syndax Pharmaceuticals | 270 |
| Zymeworks | 263 |
| Stoke Therapeutics | 128 |
| Pharvaris | 118 |
MNKD News
- 9 days ago - MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - GlobeNewsWire
- 20 days ago - MoneyShow's Best Investment Ideas For 2026: Part 5 - Seeking Alpha
- 22 days ago - 6 stocks and ETFs that these unsung market heroes see outperforming in 2026 - Market Watch
- 27 days ago - MannKind Provides Business Updates and 2026 Growth Drivers - GlobeNewsWire
- 6 weeks ago - MannKind Shares FUROSCIX® Business Updates - GlobeNewsWire
- 2 months ago - MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients - Seeking Alpha
- 2 months ago - MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - GlobeNewsWire
- 3 months ago - MannKind to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire